Vectura Group appoints Jeanne Hecht and Jeanne Thoma to its Board of Directors


Vectura Group plc (LSE: VEC) (“Vectura”, the “Group”, or the “Company”), an industry-leading specialist inhalation CDMO, is pleased to announce the appointments of Jeanne Hecht and Jeanne Thoma as Independent Non-Executive Directors of the Company with effect from 31st December 2020.

Jeanne Hecht was most recently CEO of Ora, Inc. (“Ora”) a full-service pre-clinical and clinical ophthalmic drug and device development firm. Previously she served as Chief Operating Officer and was a Board Director of Median Technologies, a clinical services imaging business. Prior to this Jeanne had a substantial career with Quintiles (later IQVIA), the world’s largest contract development services company, where she led global sales and strategic accounts.

Jeanne Thoma was most recently CEO and President of SPI Pharma, which provides specialist formulation and ingredient services to the pharmaceutical and nutritional industries, and is part of Associated British Foods plc. Previously she served as a senior advisor to the pharmaceutical industry, and has had successful careers with Lonza where, in her last role, she was President and Executive Committee Member, and BASF where she served in senior key commercial roles in their pharmaceutical solutions business. Jeanne is a member of the Boards of Directors of ANI Pharmaceuticals Inc, an integrated specialty pharmaceutical company, and Avid Bioservices Inc, a contract development and manufacturing organisation focused on the development and cGMP manufacturing of biopharmaceutical mammalian cell culture products.

Bruno Angelici, Chairman of Vectura, commented:
“I’m delighted to welcome Jeanne Hecht and Jeanne Thoma to the Board of Vectura. Jeanne Hecht brings significant experience in drug development services globally, which directly supports our new strategic direction as a leading inhalation CDMO. Jeanne Thoma brings a unique blend of commercial, HR and business leadership experience in pharmaceutical services, which will bring new domain expertise to our Board supporting our new business model.”

You can read the full announcement here.

Back to Our News

    Subscribe to our science newsletter